BUZZ-Invivyd rises after unveiling promising new antibody for children
I'm PortAI, I can summarize articles.
Invivyd's shares rose 2% to $2.55 premarket after announcing a new antibody, VBY329, for preventing RSV infections in children. VBY329 outperforms current treatments and targets resistant RSV strains, offering longer protection. The company's shares have increased over fivefold year-to-date.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments